Not found

Mauro Ferrari, PhD

Ernest Cockrell, Jr. Presidential Distinguished Chair, Houston Methodist Hospital
President & Professor of Nanomedicine, Institute for Academic Medicine
Chief Commercialization Officer and Executive Vice President, Houston Methodist
Senior Associate Dean and Professor of Medicine, Weill Cornell Medical College

Research Lab

Mauro Ferrari, PhD, is the Chief Commercialization Officer and Executive Vice President of Houston Methodist, and the President of the Houston Methodist Institute for Academic Medicine where he is the Ernest Cockrell Jr. Presidential Distinguished Chair. Ferrari leads enterprise commercializatin strategies as the CCO and as president of the Houston Methodist Institute for Academic Medicine, Ferrari oversees all research and education programs at Houston Methodist. This includes over 630 academic faculty and their research. He also serves as the Senior Associate Dean of the Weill Cornell Medical College, the primary academic affiliate of Houston Methodist and holds Adjunct and Honorary Professorships at many universities around the world.

Ferrari is the founder of biomedical nano/micro-technology, especially in their applications to drug delivery, cell transplantation, implantable bioreactors, and other innovative therapeutic modalities. Dr. Ferrari served as special expert on nanotechnology at the National Cancer Institute in 2003-2005, providing leadership for the formulation, refinement, and approval of the NCI's Alliance for Nanotechnology in Cancer, currently the world's largest program in medical nanotechnology.

He has to his credit more than 350 publications, including seven books and is the inventor of 30 issued patents in the US and Europe. Throughout his academic career, he has supervised trainees and students who have gone on to senior faculty positions at premier universities like Oxford, Massachusetts Institute of Technology (MIT), University of California Berkeley, University of California San Francisco, Duke University, University of Washington, and Ohio State University. Dr. Ferrari's degrees are in Mathematics (Padova, Italy), and Mechanical Engineering (M.S., & Ph.D., U.C. Berkeley).

His seminal contributions to the field of biomedical nanotechnology have been recognized through numerous awards and accolades, including: Founders Award - Controlled Release Society, the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship, the ETH Zürich Stodola Medal, Blaise Pascal Medal in Biomedical Engineering - European Academy of Sciences, and the Shannon Director's Award of the National Institutes of Health. Dr. Ferrari is a Fellow of the American Society of Mechanical Engineers, American Academy for the Advancement of Science and American Institute for Medical and Biological Engineering. He also holds honorary doctorates in Electrical Engineering and Biotechnology from the University of Palermo and the University of Naples “Federico II”, respectively.

His career research and development portfolio totals over $50 million, including support from the NCI, NIH, DoD, NASA, NSF, DARPA, DoE, the state of Texas, the state of Ohio, the Ohio State University, and several private enterprises. He began his academic career at the University of California, Berkeley, where he tenured in Material Science, Civil Engineering, and Bioengineering. Upon recruitment to the Ohio State University, he served as the Edgar Hendrickson Professor of Biomedical Engineering, Professor of Internal Medicine, Mechanical Engineering and Materials Science. He was also the Associate Vice President, Health Sciences Technology and Commercialization, Associate Director of the Dorothy M. Davis Heart and Lung Research Institute and Director of the Biomedical Engineering Center. Upon recruitment to Houston, he served as professor and chair of the nanomedicine department at the University of Texas Health Science Center. He joined Houston Methodist in 2010 as the President & CEO of the Houston Methodist Research Institute, and was appointed Chief Commercialization Officer and President of the Institute for Academic Medicine in 2018.

Description of Research

Nanomedicine for oncology, traumatic injury, cardiovascular disease, infectious pathologies, and diabetes
Biomedical Microtechnology (BioMEMS)
Drug delivery
Proteomics and peptidomics for early detection and therapeutic monitoring
Cell transplantation, regenerative medicine, and tissue engineering
Biosensors and bioseparation technology
Multiscale discrete/continuum mechanics and biomechanics

Areas Of Expertise

Nanomedicine Nanofluidics Cancer Drug delivery Biomedical microtechnology (BioMEMS)
Education & Training

Dottore, Universita' di Padova
PhD, University of California Berkeley

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity

Patent Number: AU2016243027, Nov 23 2017


Patent Number: EP3027264, Jun 08 2016

Nanochanneled device with electrodes and related methods

Patent Number: CN105530988, Apr 27 2016


Patent Number: HK1209626, Apr 08 2016


Patent Number: HK1164179, Oct 30 2015

View All

Nanoparticles in the intra-cranial treatment of brain tumors. Keystone Symposia: Cancer Metastasis: The Role of Metabolism, Immunity and the Microenvironment (M2): Keystone Symposia: Cancer Metastasis: The Role of Metabolism, Immunity and the Microenvironment (M2), Florence, Italy, March 15-19, 2019
Mattu, C, Brachi, G, Ciardelli, G, Blanco, E, Rostomily, RC, Mikheev, A & Ferrari, M 2019, .

Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance
Ziemys, A, Yokoi, K, Kai, M, Liu, YT, Kojic, M, Simic, V, Milosevic, M, Holder, AM & Ferrari, M 2018, Journal of Controlled Release, vol. 291, pp. 99-105.

Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale
Bruno, G, Di Trani, N, Hood, RL, Zabre, E, Filgueira, CS, Canavese, G, Jain, P, Smith, Z, Demarchi, D, Hosali, S, Pimpinelli, A, Ferrari, M & Grattoni, A 2018, Nature communications, vol. 9, no. 1, 1682.

Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple-negative breast cancer
Mu, C, Wu, X, Zhou, X, Wolfram, J, Shen, J, Zhang, D, Mai, J, Xia, X, Holder, AM, Ferrari, M, Liu, X & Shen, H 2018, Clinical Cancer Research, vol. 24, no. 19, pp. 4900-4912.

Biophysical roles of platelets in the pre-metastatic niche on transport of circulating tumor cells
Yokoi, K, Kojic, M, Ferrari, M & Ziemys, A 2018, 2018 CSBC/PS-ON Annual Investigators Meeting , Bethesda, United States, 9/25/18 - 9/28/18, .

Design of multi-functional core-shell nanoparticles and investigation of their transport kinetics after intra-cranial injection in a brain cancer model: 16th International Nanomedicine & Drug Delivery Symposium. Portland, Oregon, September 21-23, 2018
Brachi, G, Ciardelli, G, Rostomily, RC, Blanco, E, Mikheev, A, Ferrari, M & Mattu, C 2018, .

Correction function for accuracy improvement of the Composite Smeared Finite Element for diffusive transport in biological tissue systems
Milosevic, M, Simic, V, Milicevic, B, Koay, EJ, Ferrari, M, Ziemys, A & Kojic, M 2018, Computer Methods in Applied Mechanics and Engineering, vol. 338, pp. 97-116.

A visually apparent and quantifiable CT imaging feature identifies biophysical subtypes of pancreatic ductal adenocarcinoma
Koay, EJ, Lee, Y, Cristini, V, Lowengrub, JS, Kang, Y, San Lucas, FA, Hobbs, BP, Ye, R, Elganainy, D, Almahariq, M, Amer, AM, Yu, S, Chatterjee, D, Yan, H, Park, PC, Rios Perez, MV, Li, D, Garg, N, Reiss, K, Chauhan, A, Zaid, MM, Nikzad, N, Wolff, RA, Javle, M, Varadhachary, GR, Shroff, RT, Das, P, Lee, JE, Ferrari, M, Maitra, A, Taniguchi, CM, Kim, MP, Crane, CH, Katz, MHG, Wang, H, Bhosale, P, Tamm, EP & Fleming, JB 2018, Clinical Cancer Research.

Multiscale smeared finite element model for mass transport in biological tissue: From blood vessels to cells and cellular organelles
Kojic, M, Milosevic, M, Simic, V, Koay, EJ, Kojic, N, Ziemys, A & Ferrari, M 2018, Computers in Biology and Medicine, vol. 99, pp. 7-23.

Nanotherapeutics for treatment of pulmonary arterial hypertension
Segura-Ibarra, V, Wu, S, Hassan, N, Moran-Guerrero, JA, Ferrari, M, Guha, A, Karmouty-Quintana, H & Blanco, E 2018, Frontiers in Physiology, vol. 9, no. JUL, 890, pp. 890.

DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement
Mai, J, Li, X, Zhang, G, Huang, Y, Xu, R, Shen, Q, Lokesh, GL, Thiviyanathan, V, Chen, L, Liu, H, Zu, Y, Ma, X, Volk, DE, Gorenstein, DG, Ferrari, M & Shen, H 2018, Molecular Pharmaceutics, vol. 15, no. 5, pp. 1814-1825.

Inflammation-targeted vascular nanomedicine
Cooke, JP & Ferrari, M 2018, Nature Biomedical Engineering, vol. 2, no. 5, pp. 269-270.

Distribution of glutathione-stabilized gold nanoparticles in feline fibrosarcomas and their role as a drug delivery system for doxorubicin—preclinical studies in a murine model
Zabielska-Koczywas, K, Wojtalewicz, A, Uzarowska, E, Klejman, A, Wojtkowska, A, Dolka, I, Wojnicki, M, Sobczak, K, Wójcik, M, Shen, H, Ferrari, M & Lechowski, R 2018, International Journal of Molecular Sciences, vol. 19, no. 4, 1021.

SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy
Wang, F, Xia, X, Yang, C, Shen, J, Mai, J, Kim, HC, Kirui, D, Kang, Y, Fleming, JB, Koay, EJ, Mitra, S, Ferrari, M & Shen, H 2018, Clinical Cancer Research, vol. 24, no. 13, pp. 3176-3185.

Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes
Mujoo, K, Hunt, CR, Pandita, RK, Ferrari, M, Krishnan, S, Cooke, JP, Hahn, S & Pandita, TK 2018, Molecular Cancer Research, vol. 16, no. 8, pp. 1209-1214.

Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Zhu, M, Ding, X, Zhao, R, Liu, X, Shen, H, Cai, C, Ferrari, M, Wang, HY & Wang, RF 2018, Journal of Controlled Release, vol. 272, pp. 72-82.

Nanofluidics for cell and drug delivery
Di Trani, N, Grattoni, A & Ferrari, M 2018, . in 2017 IEEE International Electron Devices Meeting, IEDM 2017. vol. Part F134366, Institute of Electrical and Electronics Engineers Inc. pp. 40.6.1-40.6.4, 63rd IEEE International Electron Devices Meeting, IEDM 2017, San Francisco, United States, 12/2/17.

A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells
Liu, H, Mai, J, Shen, J, Wolfram, J, Li, Z, Zhang, G, Xu, R, Li, Y, Mu, C, Zu, Y, Li, X, Lokesh, GL, Thiviyanathan, V, Volk, DE, Gorenstein, DG, Ferrari, M, Hu, Z & Shen, H 2018, Theranostics, vol. 8, no. 1, pp. 31-44.

Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration
Wu, S, Zhang, A, Li, S, Chatterjee, S, Qi, R, Segura-Ibarra, V, Ferrari, M, Gupte, A, Blanco, E & Hamilton, DJ 2018, Advanced Science, vol. 5, no. 3, 1700530, pp. 1700530-n/a.

Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration
Wu, S, Zhang, A, Li, S, Chatterjee, S, Qi, R, Segura-Ibarra, V, Ferrari, M, Gupte, A, Blanco, E & Hamilton, DJ 2018, Advanced Science, vol. 5, no. 3, 1700530, pp. 1700530-n/a.